Aurora Martinez is the leader of the research group Biorecognition that studies the relation between biomolecular structure and function to understand and develop new therapeutic options for genetic diseases, notably neurometabolic disorders such as phenylketonuria (PKU) and defects in dopamine synthesis.
Aurora is also a partner in the KG Jebsen Centre for neuropsychiatric disorders. In addition, she is also a partner in the project 'Molecular control of Arc protein: Decoding a master regulator of synaptic plasticity and cognition', coordinated by Clive Bramham, which received support from the Toppforsk Program (NFR).
- (2022). Structural mechanism for tyrosine hydroxylase inhibition by dopamine and reactivation by Ser40 phosphorylation. Nature Communications.
- (2022). Screening for modulators of vesicular monoamine transporter 2 activity in transfected Hek293 cells using a fluorescent substrate.
- (2022). Inhibition of VMAT2 by β2-adrenergic agonists, antagonists, and the atypical antipsychotic ziprasidone. Communications Biology. 1-14.
- (2022). High-affinity anti-Arc nanobodies provide tools for structural and functional studies. PLOS ONE.
- (2022). Does alpha-Synuclein modulate Tyrosine Hydoxylase activity?
- (2022). Biochemical and biophysical characterisation of HMBS variants associated with acute intermittent porphyria.
- (2021). The Pah-R261Q mouse reveals oxidative stress associated with amyloid-like hepatic aggregation of mutant phenylalanine hydroxylase. Nature Communications. 15 pages.
- (2021). Personalized medicine to improve treatment of dopa-responsive dystonia—a focus on tyrosine hydroxylase deficiency. Journal of Personalized Medicine. 28 pages.
- (2021). Cysteine modification by ebselen reduces the stability and cellular levels of 14-3-3 Proteins. Molecular Pharmacology. 155-169.
- (2021). Characterization of porphobilinogen deaminase mutants reveals that arginine-173 is crucial for polypyrrole elongation mechanism. iScience.